Call Us 24x7

0536-5126876

About Us

Introduction to

Bellastem Biotechnology Limited

Founded in March 2014 by a group of returned oversea doctors and located in the High-tech Zone of Gaomi City, Shandong Province, Bellastem Biotechnology Limited(BBL) now stands as a state-level hi-tech enterprise providing biotech services of tumor biotherapy, R&D and clinical application of stem cells as well as genetic detection http://kop-viagra.net/kop-cialis-pa-natet .

BBL has a high-level talent team with solid professional skills, which has 1 external academician, 7 external doctor’s degree holders,5 doctor’s degree holders,15 master’s degree bearer and nearly 100 bachelor’s degree or above possessor. With all the equipment imported from abroad and a complete quality control system required by GMP, BBL has built a 3000㎡-sized, 10K, partly hundred level sterile and modernized immune cell lab which has reached international advanced level and accords with the standard of FDA, GMP and Good manufacture practice for sterile medical devices (YY0033-2000). The company has established Weifang Stem Cell and Immunotherapy Engineering Technology Research Center, Weifang Key Laboratory of Cellular and Genetic Engineering and Weifang Genetic Disease Genetic Testing Engineering Research Center. Particularly, BBL established the first, also the only Med Lab in the city of Weifang, which has medical examination and practice qualifications in specialities of clinical immunology, serology and clinical cellular molecular genetics, etc.

Always holds “the world’s leading medical technology for China ” as its mission and to provide high-end medical technology services for all patients in China, BBL conducts active and deep cooperation with other trusted scientific research and medical institutions at home and abroad, focusing on R&D and application of life sciences and cutting-edge biomedical technology, facilitates transformation of scientific research achievement, strongly promotes industrialization of R&D, production and sales of series products of stem cells and cell culture medium and continuously improves the level of biological cell immunotherapy.

Development path

  • In March 2014, the company was founded in the High-tech Zone of Gaomi City, Shandong Province with a registered capital of 13 million RMB.
  • In October 2014, with 33 million RMB as its first-stage project investment, the company established a 3000 ㎡-sized purification laboratory, which accords with EU standards and has passed the inspections of CDC of Shandong Province.
  • In June 2015, the company established Weifang stem cell and immunotherapy engineering technology research center.
  • In September 2015,the company established Weifang key laboratory of cellular and genetic engineering
  • In April 2016,the company established Weifang genetic disease genetic testing engineering research center.
  • In September 2016,the company established the first Medical Detection Institute in Weifang city.
  • In December 2016, the company was identified as a state-level hi-tech enterprise by the Ministry of Science and Technology

Latest news

Deputy Director of the Standing Committee of Shandong Provincial People’s Congress,Chairwoman of Provincial Federation of Industry and Commerce Visited Bellastem

30/09/2020

On September 28, Wang Suilian, deputy director of the Standing Committee of the Provincial People's Congress and chairwoman of the Provincial Federation of Industry and Commerce, paid a visit to Bellastem Biotechnology Ltd. to understand the production and operation of the company, listen to our development appeals, and help us solve practical difficulties. Wang Zhaohui, member of the Standing Committee of Weifang Municipal Party Committee and Minister of United Front, Li Shilai, Vice Chairman of Weifang CPPCC and chairman of the Municipal Federation of Industry and Commerce, and Bian Hanlin, Secretary of Gaomi Municipal Party Committee accompanied her on the activities.

According to the official information, by the end of February 11, 2020, a total of 44,726 confirmed cases of novel coronavirus infection had been reported, and up to 21,675 people are suspected cases. The numbers of daily confirmed and suspected cases are growing at thousand for the counting unit. The prevention and control of new coronavirus pneumonia has entered a critical period. Since the outbreak, people not only use all kinds of ways of traditional medical therapy to address the epidemic, but also high and new technologies are joining in the war, such as precision medicine and stem cell research.

    
BBL’s Anti-epidemic Action is Underway

On January 29, 2020 in the United States, Sorrento Therapeutics and Celularity jointly announced the start of clinical cooperation, with the purpose of extending Celularity’s CYNK - 001 (a allogeneic and placental origin natural killer cell therapy) to the treatment and prevention of coronavirus infection, in particular, novel coronaviruses (2019-ncov) emerging in 2019.

Natural Killer Cells (NK) are the basis of the innate immune response. The company's research shows that placenta-derived NK cells are well tolerated, safe and versatile, and can be used in a wide range of organs and tissues. The potential of NK cell therapy for the treatment of various solid tumors is currently being investigated, and NK cell t...

The Development Tendency in Global Stem Cell Industry (Part One)

22/12/2019

Guide:The clinical application of stem cell medical technology was originated from 1968, when there appeared the first bone marrow transplantation in the world and treated a patient with severe combined immunodeficiency(SCID), which opened the door of application to stem cell in medicine. Currently, stem cells have been used to treat more than 140 diseases and are in clinical trials, and tens of thousands of stem cell transplants has been performed.

Global Stem Cell Therapy is Growing Rapidly,and Will Reach $400 Billion by 2020

The stem cell industry chain contains three parts: cell collection, preparation and storage in upstream, cell proliferation, cell differentiation and pharmaceutical preparation R&D in midstream and cl...

The Development Tendency in the Global Stem Cell Industry(Part Two)

22/12/2019

Guide:With a series of promote policies for the development of stem cell industry in China, relevant departments and units have responded positively to the call,and followed the development tendency to accelerate the development of stem cell research and transformation projects. According to statistical data, from the launch of the first batch of national key R&D plan pilot projects in 2015, the key projects has been supported by the Central Finance for four consecutive years: 25 projects with 480 billion yuan support in 2016;43 projects with 940 billion yuan in 2017; 30 projects with 580 billion yuan in 2018,and the Central Finance grant 400 billion yuan to support 12 stem cell research directions in 2019, for totally 2.5 billion yuan, which fully reflects that China pays high attent...

Vigorously Develop Cell Industry: National and Local Policies in 2019 to Encourage Cell Industry

23/12/2019

Cell and gene therapy is one of the most potential field to develop in biomedical industry, and also the important direction for life and health industry. As a disruptive innovative technology, cell therapy is expected to overcome cancers, premature senility and other key diseases. The global cell market is expected to reach a trillion dollars by 2030. At the same time, China has given strong support to the health industry, especially the clinical research of cell technology and products, and national competent authorities and local governments have issued a number of favorable policies.  In 2019, China has issued a series of policies to standardize and promote the clinical research and transformation application of stem cell therapy, providing a guarantee for the...